Atea Pharmaceuticals (AVIR) Stock Forecast, Price Target & Predictions

OverviewOwnership Financials Chart Transcripts

AVIR Stock Forecast

Atea Pharmaceuticals stock forecast is as follows: an average price target of $6.88 (represents a 115.67% upside from AVIR’s last price of $3.19) and a rating consensus of 'Hold', based on 1 wall street analysts offering a 1-year stock forecast.

AVIR Price Target

The average price target for Atea Pharmaceuticals (AVIR) is $6.88 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $6.88 to $6.88. This represents a potential 115.67% upside from AVIR's last price of $3.19.

AVIR Analyst Ratings

Hold

According to 1 Wall Street analysts, Atea Pharmaceuticals's rating consensus is 'Hold'. The analyst rating breakdown for AVIR stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 1 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Atea Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 12, 2024	Matthew Harrison	Morgan Stanley	$6.88	$3.35	105.37%	115.67%

The latest Atea Pharmaceuticals stock forecast, released on Aug 12, 2024 by Matthew Harrison from Morgan Stanley, set a price target of $6.88, which represents a 105.37% increase from the stock price at the time of the forecast ($3.35), and a 115.67% increase from AVIR last price ($3.19).

Atea Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$6.88
Last Closing Price	$3.19	$3.19	$3.19
Upside/Downside	-100.00%	-100.00%	115.67%

In the current month, the average price target of Atea Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Atea Pharmaceuticals's last price of $3.19. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 12, 2024	Morgan Stanley		Equal-Weight	Upgrade

Atea Pharmaceuticals's last stock rating was published by Morgan Stanley on Aug 12, 2024. The company Upgrade its AVIR rating from "null" to "Equal-Weight".

Atea Pharmaceuticals Financial Forecast

Atea Pharmaceuticals Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$192.18M	$32.81M	$60.39M	$65.98M	$48.63M
Avg Forecast	$6.58M	$50.45M	$33.03M	$22.42M	$1.51M	-	-	-	-	-	-	$108.45M	$3.33M	$85.73M	$53.47M	$58.00M	$31.61M	$45.00M
High Forecast	$6.58M	$50.45M	$33.03M	$22.42M	$1.51M	-	-	-	-	-	-	$130.14M	$3.33M	$85.73M	$53.47M	$58.00M	$31.61M	$45.00M
Low Forecast	$6.58M	$50.45M	$33.03M	$22.42M	$1.51M	-	-	-	-	-	-	$86.76M	$3.33M	$85.73M	$53.47M	$58.00M	$31.61M	$45.00M
# Analysts	8	8	12	8	12	-	-	-	-	-	-	17	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	2.24%	0.61%	1.04%	2.09%	1.08%

Atea Pharmaceuticals's average Quarter revenue forecast for Mar 22 based on 1 analysts is $3.33M, with a low forecast of $3.33M, and a high forecast of $3.33M. AVIR's average Quarter revenue forecast represents a -98.27% decrease compared to the company's last Quarter revenue of $192.18M (Dec 21).

Atea Pharmaceuticals EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	8	8	12	8	12	-	-	-	-	-	-	17	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	$-39.90M	$-42.17M	$121.24M	$-22.09M	$8.75M	$30.72M	$20.66M
Avg Forecast	$4.17M	$31.96M	$20.92M	$14.20M	$954.83K	-	-	-	-	-	-	$68.70M	$-47.26M	$54.31M	$33.87M	$36.74M	$20.03M	$28.51M
High Forecast	$4.17M	$31.96M	$20.92M	$14.20M	$954.83K	-	-	-	-	-	-	$82.44M	$-37.81M	$54.31M	$33.87M	$36.74M	$20.03M	$28.51M
Low Forecast	$4.17M	$31.96M	$20.92M	$14.20M	$954.83K	-	-	-	-	-	-	$54.96M	$-56.71M	$54.31M	$33.87M	$36.74M	$20.03M	$28.51M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-0.58%	0.89%	2.23%	-0.65%	0.24%	1.53%	0.72%

1 analysts predict AVIR's average Quarter EBITDA for Mar 22 to be $-47.26M, with a high of $-37.81M and a low of $-56.71M. This is -138.98% lower than Atea Pharmaceuticals's previous annual EBITDA (Dec 21) of $121.24M.

Atea Pharmaceuticals Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	8	8	12	8	12	-	-	-	-	-	-	17	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	$-34.43M	$-41.98M	$117.13M	$-28.19M	$1.54M	$30.71M	$20.66M
Avg Forecast	$-30.79M	$-35.95M	$-36.39M	$-37.53M	$-35.88M	$-35.46M	$-34.19M	$-35.04M	$-24.45M	$-36.02M	$-55.85M	$784.44M	$-47.16M	$27.37M	$-4.43M	$378.05K	$243.25M	$20.64M
High Forecast	$-30.79M	$-35.95M	$-36.39M	$-37.53M	$-35.88M	$-35.46M	$-34.19M	$-31.25M	$-20.96M	$-36.02M	$-55.85M	$941.33M	$-37.72M	$27.37M	$-4.43M	$378.05K	$291.90M	$20.64M
Low Forecast	$-30.79M	$-35.95M	$-36.39M	$-37.53M	$-35.88M	$-35.46M	$-34.19M	$-38.82M	$-26.55M	$-36.02M	$-55.85M	$627.55M	$-56.59M	$27.37M	$-4.43M	$378.05K	$194.60M	$20.64M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-0.04%	0.89%	4.28%	6.37%	4.07%	0.13%	1.00%

Atea Pharmaceuticals's average Quarter net income forecast for Mar 22 is $-47.16M, with a range of $-56.59M to $-37.72M. AVIR's average Quarter net income forecast represents a -140.26% decrease compared to the company's last Quarter net income of $117.13M (Dec 21).

Atea Pharmaceuticals SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	8	8	12	8	12	-	-	-	-	-	-	17	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	$12.36M	$12.54M	$13.19M	$11.94M	$11.90M	$8.76M	$14.14M
Avg Forecast	$4.70M	$36.07M	$23.62M	$16.03M	$1.08M	-	-	-	-	-	-	$88.31M	$2.38M	$61.30M	$38.23M	$41.47M	$22.60M	$32.18M
High Forecast	$4.70M	$36.07M	$23.62M	$16.03M	$1.08M	-	-	-	-	-	-	$105.97M	$2.38M	$61.30M	$38.23M	$41.47M	$22.60M	$32.18M
Low Forecast	$4.70M	$36.07M	$23.62M	$16.03M	$1.08M	-	-	-	-	-	-	$70.65M	$2.38M	$61.30M	$38.23M	$41.47M	$22.60M	$32.18M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.14%	5.26%	0.22%	0.31%	0.29%	0.39%	0.44%

Atea Pharmaceuticals's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to AVIR last annual SG&A of $12.36M (Dec 22).

Atea Pharmaceuticals EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	8	8	12	8	12	-	-	-	-	-	-	17	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	$-0.41	$-0.50	$1.41	$-0.34	$0.02	$0.37	$0.25
Avg Forecast	$-0.36	$-0.43	$-0.43	$-0.44	$-0.42	$-0.42	$-0.41	$-0.41	$-0.29	$-0.43	$-0.66	$-0.44	$-0.58	$0.32	$-0.05	-	$-0.05	$0.24
High Forecast	$-0.36	$-0.43	$-0.43	$-0.44	$-0.42	$-0.42	$-0.41	$-0.37	$-0.25	$-0.43	$-0.66	$-0.44	$-0.58	$0.32	$-0.05	-	$-0.05	$0.24
Low Forecast	$-0.36	$-0.43	$-0.43	$-0.44	$-0.42	$-0.42	$-0.41	$-0.46	$-0.31	$-0.43	$-0.66	$-0.44	$-0.58	$0.32	$-0.05	-	$-0.05	$0.24
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.92%	0.86%	4.34%	6.47%	4.46%	-6.83%	1.02%

According to 1 Wall Street analysts, Atea Pharmaceuticals's projected average Quarter EPS for Mar 22 is $-0.58, with a low estimate of $-0.58 and a high estimate of $-0.58. This represents a -141.31% decrease compared to AVIR previous annual EPS of $1.41 (Dec 21).

Atea Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.52	$70.00	13361.54%	Buy
ELEV	Elevation Oncology	$0.67	$9.00	1243.28%	Buy
CNSP	CNS Pharmaceuticals	$0.11	$0.50	354.55%
IMMX	Immix Biopharma	$2.29	$7.00	205.68%	Buy
AVIR	Atea Pharmaceuticals	$3.16	$6.88	117.72%	Hold

AVIR Forecast FAQ

Is Atea Pharmaceuticals a good buy?

No, according to 1 Wall Street analysts, Atea Pharmaceuticals (AVIR) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of AVIR's total ratings.

What is AVIR's price target?

Atea Pharmaceuticals (AVIR) average price target is $6.88 with a range of $6.88 to $6.88, implying a 115.67% from its last price of $3.19. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Atea Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for AVIR stock, the company can go up by 115.67% (from the last price of $3.19 to the average price target of $6.88), up by 115.67% based on the highest stock price target, and up by 115.67% based on the lowest stock price target.

Can Atea Pharmaceuticals stock reach $5?

AVIR's average twelve months analyst stock price target of $6.88 supports the claim that Atea Pharmaceuticals can reach $5 in the near future.

What are Atea Pharmaceuticals's analysts' financial forecasts?

Atea Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.51M (high $1.51M, low $1.51M), average EBITDA is $954.83K (high $954.83K, low $954.83K), average net income is $-141M (high $-137M, low $-144M), average SG&A $1.08M (high $1.08M, low $1.08M), and average EPS is $-1.665 (high $-1.62, low $-1.71). AVIR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $112.48M (high $112.48M, low $112.48M), average EBITDA is $71.25M (high $71.25M, low $71.25M), average net income is $-141M (high $-141M, low $-141M), average SG&A $80.43M (high $80.43M, low $80.43M), and average EPS is $-1.666 (high $-1.666, low $-1.666).

Did the AVIR's actual financial results beat the analysts' financial forecasts?

Based on Atea Pharmaceuticals's last annual report (Dec 2021), the company's revenue was $351.37M, beating the average analysts forecast of $228.8M by 53.57%. Apple's EBITDA was $138.38M, missing the average prediction of $144.94M by -4.53%. The company's net income was $121.19M, missing the average estimation of $266.57M by -54.54%. Apple's SG&A was $45.78M, missing the average forecast of $163.61M by -72.02%. Lastly, the company's EPS was $1.46, beating the average prediction of $0.223 by 555.81%. In terms of the last quarterly report (Dec 2021), Atea Pharmaceuticals's revenue was $192.18M, beating the average analysts' forecast of $85.73M by 124.18%. The company's EBITDA was $121.24M, beating the average prediction of $54.31M by 123.25%. Atea Pharmaceuticals's net income was $117.13M, beating the average estimation of $27.37M by 327.92%. The company's SG&A was $13.19M, missing the average forecast of $61.3M by -78.49%. Lastly, the company's EPS was $1.41, beating the average prediction of $0.325 by 334.01%